By Anuron Kumar Mitra
BENGALURU, Feb 18 (.) – India’s Bharat Biotech is in the process of submitting regulatory documents for approval of its COVAXIN vaccine against COVID-19 in more than 40 countries, the company told . late Wednesday.
“We present our documentation in Brazil and other countries and await their approval. We plan to export several million doses to Brazil,” the company said in an emailed statement.
“COVAXIN’s price for international markets will be based on delivery terms, purchase commitments and acquisition volumes,” he added.
Bharat Biotech, which had told . last Tuesday that it could ship doses of COVAXIN to Brazil and the United Arab Emirates by the end of the week, did not name other countries and did not give exact figures on the doses it expects to export.
The company also entered into an agreement with the US drug developer Ocugen Inc for the commercialization of COVAXIN in the United States, the country with the highest number of infections in the world.
COVAXIN is one of two vaccines approved for emergency use in India, although efficacy data from its late-stage trial have not yet been published.
Bharat Biotech expects the results of an ongoing trial involving 25,800 participants in India as early as March, although the country’s drug regulator has rated the vaccine as safe and effective, amid criticism from some doctors and health experts.
COVAXIN is currently being used by India in its vaccination campaign, which has already covered more than 9 million healthcare workers, and aims to immunize 300 million people by August. Bharat Biotech has supplied 5.5 million doses to the government and will sell an additional 4.5 million doses.
India, with almost 11 million cases of coronavirus, has the second highest number of infections in the world, although some experts believe that the worst of the disease is over.
(Reported by Anuron Kumar Mitra in Bengaluru; Edited in Spanish by Janisse Huambachano)